Highlights d Two CCR2A structures in complex with the orthosteric antagonist MK-0812 were solved d IMISX in situ plates facilitated high-quality diffraction data collection d Residue E291 7.39 was confirmed as important in orthosteric antagonist binding d The non-conserved residue H121 3.33 is important for CCR2 selectivity over CCR5
In Brief
Two independent structures of CCR2A in complex with the orthosteric antagonist MK-0812 were solved, confirming the importance of residue E291 7.39 for antagonist binding. Structural modeling of pyrimidine amide antagonists showed an interaction with the non-conserved H121 3.33 , leading to a significant selectivity over CCR5, suggesting strategies for highly selective CCR2 antagonist design.
Data Resources 6GPS 6GPX
INTRODUCTION CC chemokine receptor 2 belongs to the family of class A G-protein-coupled receptors (GPCRs) (www.gpcrdb.org) and exists as two splice variants, namely CCR2A and CCR2B, which differ only in the lengths of their carboxyl termini (Charo et al., 1994) . The expression of CCR2 is cell-type specific, i.e., CCR2A is the major isoform expressed by mononuclear cells and vascular smooth muscle cells (Bartoli et al., 2001) , whereas monocytes and activated natural killer cells express predominantly CCR2B (Deshmane et al., 2009; Tanaka et al., 2002) . CCR2A and CCR2B may function through different signaling pathways and perform different actions (Cho et al., 2007; Sanders et al., 2000) . Both isoforms show comparable binding affinities for their endogenous ligand CCL2, induce Ca 2+ signaling, and inhibit adenylate cyclase in various cell types (Myers et al., 1995; Preobrazhensky et al., 2000; Tian et al., 2008; Wong et al., 1997) . We focused our work on the less extensively studied isoform to give insight into the functional role of CCR2A. CCR2 is one of the most widely studied chemokine receptors involved in inflammatory diseases (Feris and Diaz-Gonzá lez, 2006) . Modified CCL2 peptides, which bind CCR2 but are unable to activate the receptor, demonstrated the therapeutic relevance of CCL2-derived inhibitors on arthritis presented in animal models (Gong and Clark-Lewis, 1995) , encouraging discovery and development of antagonists. Several classes of small-molecule CCR2 antagonists have been identified in recent studies (Carter, 2013; Xia and Sui, 2009 ). The antagonists either target competitively the orthosteric CCL2 binding site or bind to an allosteric pocket located on the intracellular side of the receptor , previously identified in other chemokine receptors (Scholten et al., 2012) . Structural details of the binding of the orthosteric antagonist BMS-681 and the allosteric ligand CCR2-RA- [R] have recently been elucidated via the crystal structure of the CCR2B receptor found in a ternary complex with both ligands (Zheng et al., 2016) . In this structure specific receptor modifications were applied in order to facilitate crystallization. Such modifications included C-terminal truncation, a T4 lysozyme (T4L) fusion within ICL3, and the use of a corresponding sequence of the M2 receptor close to the T4L insertion region between TM5 and TM6. Functional integrity of the construct was shown by ligand binding to both binding pockets and by demonstrating positive binding cooperativity of BMS-681 and CCR2-RA- [R] . Indeed, CCR2-RA-[R] allosterically enhances the binding of BMS-681 and is allosterically enhanced by the binding of the orthosteric antagonist (Zheng et al., 2016) . In chemokine receptors the orthosteric binding pocket can be divided into a major sub-pocket built by residues from transmembrane (TM) regions III-VII and a minor sub-pocket with TM regions I-III and VII (Surgand et al., 2006) . While many small-molecule ligands interact with both binding sub-pockets, BMS-681 binds mainly in the minor sub-pocket of the CCR2B receptor (Zheng et al., 2016) . CCR2-RA- [R] binds to an intracellular allosteric site, which was previously reported by Zweemer et al. (2013) and also identified in the chemokine receptor CCR9 (Oswald et al., 2016) . In particular, K 8.49 at the bottom of the allosteric binding pocket is highly conserved among chemokine receptors (68.4%), playing a major role in the interaction with several allosteric antagonists (Zweemer et al., 2014) . Biological data for CCR2 tackling areas such as inflammation, the central nervous system, metabolic diseases and cancer have encouraged multiple clinical trials (www.clinicaltrials.gov). Despite this significant investment and effort, a molecule has yet to reach the market. Challenges for the discovery and development of CCR2 targeting therapeutic molecules include the absence of a detailed understanding of the ligand-induced chemokine receptor molecular signaling, the lack of suitable model organisms, and the great redundancy of the chemokine receptor system (Solari et al., 2015) .
In this study we investigate the orthosteric antagonist MK-0812, a tetrahydropyranyl cyclopentyl tetrahydropyridopyridine derivative discovered by Merck as a dual CCR2/CCR5 antagonist (Struthers and Pasternak, 2010) . This compound showed in vivo activity by preventing the infiltration of macrophages in mouse models (Wisniewski et al., 2010) , but failed to meet clinical efficacy endpoints in phase II clinical trials for the treatment of rheumatoid arthritis and multiple sclerosis (Horuk, 2009) . We describe two crystal structures of the CCR2A receptor splice variant in complex with the orthosteric antagonist MK-0812 determined by a combination of stabilizing mutations, truncations, and a rubredoxin fusion. A high-resolution structure was determined using serial synchrotron crystallography. The data collected provide an explanation for the key role of residue E291 7.39 in orthosteric CCR2 antagonist binding. Given the challenges in CCR2 drug design, the structural information obtained in this study will contribute to the design of novel and more efficient drugs targeting CCR2, in particular by applying strategies that address issues with selectivity against other chemokine receptors.
RESULTS

Stabilization of CCR2A by Point Mutations and Rubredoxin Fusion for Crystallization
To enable CCR2A for high-resolution crystal structure determination, a combination of protein stabilization and co-crystallization strategies were applied, including point mutations (Heydenreich et al., 2015) , fusion partners (Chun et al., 2012) , and N-/C-terminal truncations, as well as co-purification with potent small-molecule antagonists (Oswald et al., 2016; Tan et al., 2013b; Zheng et al., 2016) . Detailed construct information is included in Figure S1A . Wild-type (WT) CCR2A proved to be highly unstable during purification, resulting in low yields and protein of insufficient quality (data not shown). Insertion of a rubredoxin fusion in ICL3 allowed for receptor purification and resulted in a slightly improved size-exclusion chromatography profile. The construct was analyzed using differential scanning fluorimetry (DSF) and exhibited a melting point (Tm) of 43.7 C ( Figure 1B) .
Like CCR5, which bears 71% sequence identity to CCR2A, CCR2A was successfully stabilized by introducing the four point mutations C70 1.60 Y, G175 4.60 N, A241 6.33 D, K311 8.49 E (superscripts denote Ballesteros-Weinstein nomenclature; Ballesteros and Weinstein, 1995) , and N14Q, a glycosylation site mutation. The point mutations led to significant improvement in CCR2A homogeneity ( Figure 1A ), and used in combination with the ICL3 rubredoxin fusion (leading to CCR2A-fl), they stabilized the protein to a Tm of 55.6 C ( Figure S2A ).
The Orthosteric Antagonist MK-0812 Increases the Thermal Stability of CCR2A and Enables Crystallization
To further stabilize the receptor we screened a series of CCR2 antagonists (Table S1 ) from different structural classes on CCR2A-fl by DSF ( Figure 2 ). The orthosteric antagonist MK-0812 showed the highest stabilization, being 12.5 C from the original Tm (Tm = 68.1 C), and was therefore used in subsequent crystallization trials with CCR2A-fl. Crystals of this construct were obtained by lipidic cubic phase (LCP) crystallization and were used to determine an initial structure of CCR2A at 3.3 Å (CCR2A-fl).
N-and C-Terminal Truncation of CCR2A Is Mandatory for Reproducible Crystallization
Despite such improvement, the reproducibility of the crystallization trials using the full-length construct was relatively low; in addition, on closer inspection, it was observed that crystals were obtained only when both N and C termini of the receptor were cleaved by proteolysis upon storage. N-terminal sequencing of CCR2A after a few days (>2) of storage identified G29 as the first residue of the N-terminally truncated form. The optimal C terminus was identified via DSF experiments with progressive truncations at defined positions (using CCR5 as a model). Here the highest thermal stability was found when truncating 53 amino acids up to G321 ( Figure S2B ), which coincidentally is the last amino acid resolved in the electron density of our structure CCR2A-fl. We therefore re-engineered the crystallization construct by truncating 28 amino acids at the N terminus and 53 amino acids at the C terminus (CCR2A-DN.C), which shared a Tm in DSF experiments comparable to that of the fulllength protein (Tm apo = 55.5 C, Figure S2B ). To allow co-crystallization with both orthosteric and allosteric ligands as previously described (Zheng et al., 2016) , we reverted the K311 8.49 E mutation in CCR2A-DN.C, resulting in CCR2A-DN.C (À). We reasoned that the K311 8.49 E mutation close to the allosteric pocket may reduce the affinity of allosteric antagonist binding. The reversion of K311 8.49 E to the WT sequence K311 8.49 indeed led to a significant decrease in thermal stability relative to CCR2A-DN.C (DTm = À6.0 C) ( Figures S2C and S2D ). Interestingly, this decrease in stability was well compensated by the addition of MK-0812 (DTm = 10.5 C versus 15.5 C), resulting in thermal stability similar to that of the MK-0812-bound constructs CCR2A-DN.C and CCR2A-DN.C (À) ( Figures S2C and S2D ). With CCR2A-DN.C (À) we were able to reproducibly generate crystals of high quality ( Figure S3A ) and determined a high-resolution structure of CCR2A in complex with MK-0812 at 2.7 Å resolution (structure CCR2A-DN.C (À)). Serial crystallographic data collection was facilitated by adopting an approach based on the employment of in meso in situ serial X-ray crystallography (IMISX) (Huang et al., 2015) . This methodology greatly increases throughput by avoiding the laborious harvesting and data collection screening of individual crystals, as well as minimizing mechanical damage to crystals during harvesting and freezing. Crystal screening, data collection, and merging are handled by automated scripts at the Swiss Light Source beamline . In total, 220 mini-datasets, corresponding to 10 crystal rotation each, were collected; 130 of those were processed followed by merging of 77 to give a final 2.7 Å dataset.
Despite the presence of the allosteric antagonist CCX140 during crystallization, no density for the ligand could be observed.
Effects of Point Mutations N14Q, C70Y 1.60 , G175N 4.60 , A241D 6.33 , and K311E 8.49 ; Rubredoxin Fusion; and Cand N-Terminal Truncations on CCL2 and MK-0812 Binding To obtain the crystal structure of human CCR2A we introduced five and three amino acid substitutions into CCR2A-fl and CCR2A-DN.C (À), respectively, which are described in Fig Figure S1A . Both WT CCR2B (CCR2B-WT) and CCR2A full-length rubredoxin fusion, including the five point mutations N14Q, C70 1.60 Y, G175 4.60 N, A241 6.33 D, and K311 8.49 E (CCR2A-fl), exhibited half maximal inhibitory concentration (IC 50 ) values between 0.53 and 1.96 nM, comparable with previously reported IC 50 values (0.15-1.9 nM), depending on the cell line, buffer composition, and expression levels (Kuang et al., 1996; Sanders et al., 2000) . Therefore, the rubredoxin fusion and the five point mutations N14Q, C70 1.60 Y, G175 4.60 N, A241 6.33 D, and K311 8.49 E have negligible effects on CCL2 binding in comparison with CCR2B-WT ( Figure S4B ). C-terminal truncation up to 53 amino acids did not affect ligand binding (CCR2A-DC, Figure S4E ), while N-terminal truncation of 28 amino acids abolished CCL2 binding, as expected (CCR2A-DN, Figure S4D and CCR2A-DN.C, data not shown). When we analyzed the small-molecule antagonist MK-0812 in competition experiments using radioactive 125 I-CCL2, we found that it competes in physiological ligand binding with comparable efficacy for binding of CCR2B-WT and CCR2A modified for crystallization. The IC 50 values of 2.04 nM for CCR2B-WT and 8.11 nM for CCR2A-fl (À) are in the range of the IC 50 of 5 nM described by Struthers and Pasternak (2010) . The CCR2A-fl-derived Tm values with the CCR2 antagonists MK-0812, INCB3344 (Xue et al., 2010) , and INCB3284 (Xue et al., 2011) are in good correlation with the Ki values of CCR2B ( Figure 2B ). Furthermore the correlation plot carries additional information on the effect of the mutations in CCR2A-fl. For instance, for compound Ex15, which is directly affected by the G175N mutation, the correlation is not observed. While the presence of the rubredoxin fusion in ICL3 and the A241 6.33 D mutation prevented receptor activation (data not shown), the unaffected binding affinity of MK-0812 suggests that the crystallization constructs CCR2A-fl and CCR2A-DN.C (À) are suitable structural surrogates to study ligand binding.
Overall Structural Architecture of CCR2A with the Orthosteric Antagonist MK-0812
We have solved two independent structures of CCR2A. Structure CCR2A-fl was determined to 3.3 Å resolution in space A B group P2 1 with one molecule in the asymmetric unit. Structure CCR2A-DN.C (À) was determined to 2.7 Å resolution in a different crystal system of the same space group, with two molecules found in the asymmetric unit. One of the molecules in the asymmetric unit is structurally resolved in its entirety, whereas in the other molecule the rubredoxin domain and helix 8 are disordered ( Figures S3D and S3E ). Details of data collection and refinement statistics are shown in Table 1 .
CCR2A exhibits the canonical 7 TM domain topology, interconnected by three extracellular and three intracellular loops, followed by helix 8 on the intracellular face of the receptor (Figures 3A and 3B) . N-terminal residues are not well defined in the electron density (first residues observed in CCR2A-fl and CCR2A-DN.C (À) are V37 1.27 and F35, respectively). Intracellular C-terminal residues are resolved up to G321 in structure CCR2Afl and up to E322 (E322 remained from a PreScission protease cleavage site) in structure CCR2A-DN.C (À). CCR2A is predicted to have two disulfide bridges: one connecting the N terminus to ECL3 (C32-C277), as described for CCR9 (Oswald et al., 2016) and CCR5 (Tan et al., 2013a , 2013b , and one connecting TM3 to ECL2 (C113 3.25 -C190 ECL2 ). In our structure, the electron density is visible only for C113 3.25 -C190 ECL2 , similar to CCR2B (Zheng et al., 2016) . However, since the N-terminal disulfide bridge is crucial for CCL2 binding (Monteclaro and Charo, 1997) , and binding activity of CCR2A-fl with CCL2 was demonstrated in a radioactive binding assay ( Figure S4 ), we assume that the disulfide bridge is most likely formed in our CCR2A construct. The fact that this disulfide is not observed in the crystal structures is probably attributable to radiation damage (Weik et al., 2000) .
The refined structures CCR2A-fl and CCR2A-DN.C (À) are very similar, with root-mean-square deviation (RMSD) values of 0.40 and 0.41 Å between equivalent Ca atoms in structure CCR2A-fl (chain A) and in CCR2A-DN.C (À) (chains A and B). Major differences are observed in the position of helix 8 relative to the TM7 core. In structure CCR2A-fl, helix 8 is inclined by 30 , whereas in chain A of structure CCR2A-DN.C (À), it lies parallel to the lipid bilayer ( Figure 3C ). The differences in the orientation of helix 8 are probably due to distinct crystal packing interac- tions, as helix 8 is in proximity to the rubredoxin domain of a neighboring protomer in both structures, but in significantly different positions, which impact the conformation ( Figures S3D and S3E ). We conclude from this observation that helix 8 in our constructs is conformationally flexible and the observed orientation relative to the TM7 domain is dictated by the particular crystal environments. The structures are also similar to the previously published CCR2 isoform B structure (PDB: 5T1A) (Zheng et al., 2016) with an RMSD of 0.46 Å between equivalent Ca atoms ( Figure 3B ). This confirms that stabilizing mutations and introduction of different fusion proteins to enhance crystallization have little impact on the overall structure of the receptor. The amino acid sequences of the two CCR2 isoforms differ solely in the carboxy-terminal region (Charo et al., 1994) , following residue R313 8.51 ( Figure S1C ). The additional amino acid residues present in our CCR2A construct do not lead to any structural difference. In 5T1A the orientation of helix 8 is similar to that found in chain A of structure CCR2A-DN.C (À); and the last three helical turns on the intracellular side of TM5/6 are rotated slightly outward, away from the receptor helical core ( Figure 3D ). This is most likely due to a difference in the nature of the fusion protein inserted into ICL3 (T4L versus rubredoxin, Figure 3B ) and the presence or absence of allosteric antagonists in the intracellular G-protein-coupling pocket of CCR2. In the following section, we discuss details of the receptor structure and the ligand binding site of chain A of structure CCR2A-DN.C (À), selected due to higher quality crystallographic data of structure CCR2A-DN.C (À) and the completeness of the model of chain A.
MK-0812 and BMS-681 Form Similar Contacts within the Orthosteric Binding Pocket MK-0812 is well defined in the electron density, which allows accurate positioning of the ligand in the binding site (Figure 4A ). MK-0812 in our structure and BMS-681 in the CCR2B complex occupy overlapping positions in the orthosteric pocket.
The bicyclic ring systems of both antagonists overlap in a subpocket between TM1 and TM7 ( Figure 4C ) and the trifluoromethyl groups of both ligands protrude into the lipid bilayer. The tetrahydropyran ring of MK-0812 superimposes on the tertiary amine moiety of BMS-681 and adopts a chair conformation. It sits above Y120 3.32 , with a water molecule mediating a hydrogen bonding interaction between the ring oxygen and the hydroxyl group of T179 4.64 . The methoxy group points toward the conserved disulfide bridge C113 3.25 -C190 ECL2 , found between the upper part of TM3 and ECL2. The bridging cyclopentane group of MK-0812 lies on top of the side chain of W98 2.60 , similar to the cyclohexane ring in BMS-681. The alkyl substituents of both antagonists nicely superimpose and point toward the b-carbon atoms of the S101 2.63 and A102 2.64 side chains located at the top of TM2, facing the solvent-filled region of the entrance to the orthosteric pocket. Despite being located on different molecular trajectories, the carbonyl group of the g-lactam ring of BMS-681 and the bridging carbonyl group of MK-0812 occupy identical positions, which enable hydrogen bonding (2.9 Å ) to the side chain hydroxyl of Y49 1.39 .
Interestingly, there are two main differences between the interaction modes of the two antagonists MK-0812 and BMS-681. These compounds differ mainly in the structure and connectivity of their central bridging moieties. This results in diverging trajectories of the attached substituents within the orthosteric pocket. Thus, the g-lactam ring in BMS-681 sits deeper in the orthosteric pocket and pushes away the E291 7.39 side chain from a position that is observed in the MK-0812 complex. Therefore, while a hydrogen bond between the E291 7.39 side chain and Y120 3.32 (2.9 Å distance) is retained in both structures, the secondary amine of MK-0812 forms a charge-reinforced hydrogen bond to the other carboxylate oxygen of E291 7.39 (2.5 Å distance), whereas the BMS-681 tertiary amine residues cannot form any interaction with the protein.
Residues Y49 1.39 , W98 2.60 , Y120 3.32 , and E291 7.39 are involved in ligand binding and are important for CCL2 binding and/or receptor activation (Berkhout et al., 2003; Hall et al., 2009) . Based on the structural information, MK-0812 acts as a competitive inhibitor regarding CCL2 binding. We performed radioligand binding assays ( Figures S4G-S4I ), which provide further evidence for this mode of action. In summary, the orthosteric binding pockets of the BMS-681 and MK-0812 structures are very similar, with the main difference residing in the side chain conformation of E291 7.39 due to different spatial requirements of the bridging regions between the overlapping portions of the ligands.
Using the Structural Information to Rationalize Structure-Activity Relationships in the MK-0812 Class Numerous studies have been carried out on the structure-activity (SAR) and structure-kinetic relationships (SKR) of CCR2 receptor antagonists based on the cyclopentane Struthers and Pasternak, 2010; Vilums et al., 2015b; Yang et al., 2007; Zheng et al., 2011) or octahydropentalene scaffold (Cai et al., 2013) , decorated with different heterocyclic ring systems. Substitution of the trifluoromethyl group on MK-0812 with Br or Cl decreased the antagonist activity between 3-and 10-fold (Cai et al., 2013) , while replacement with hydrogen completely abolished CCR2 binding. This SAR indicates the importance of a strong electron-withdrawing group at this position in the heterocycle and may, in part, be caused by the position of this substituent at the interface to the lipid bilayer. The immediate protein environment consists mainly of aliphatic side chains, namely I40 1.30 , G41 1.31 , L44 1.34 , L45 1.35 , Q288 7.36 , and V289 7.37 . In addition, two potential H-bond acceptors, the carbonyl oxygen of V37 1.27 and the hydroxyl oxygen of T292 7.40 , may form favorable interactions with positively polarized aromatic hydrogens of the pyridine ring. In our structure the pyridine nitrogen does not make any direct contact with CCR2, but it is hydrogen bonded to a nearby water molecule. This is in line with the observation that replacement of this nitrogen atom with a carbon atom did not significantly affect CCR2 activity (Cai et al., 2013) . Moreover, SKR studies on cyclopentane-based CCR2 antagonists (Vilums et al., 2013 (Vilums et al., , 2015b revealed that replacement of the methoxy-tetrahydropyran ring with a 5-trifluoro-or 5-Br-substituted 2,3-dihydro-1H-indene ring significantly increased the CCR2 residence time (t = 667 and 714 min) compared with 92 min for MK-0812 (Vilums et al., 2015a) without improving the Ki. Modeling the 5-Br-substituted analog (compound 15a) into the MK-0812 structure revealed an extension of the 5-Br-2,3-dihydro-1H-indene ring toward the main orthosteric binding pocket of TM4 and TM5. This results in enhanced lipophilic contacts with residues Y120 3.32 , P192 ECL2 , and F194 ECL2 , replacing at least two water molecules that are present when MK-0812 binds ( Figure 4E ). Furthermore, the Br substituent points into a hydrophilic region comprising H121 3.33 and H202 5.38 , thereby enhancing the formation of additional hydrogen bonds to the ligand. The diastereomer compound 15b occupies a similar region in the CCR2 binding site ( Figure S5) ; however, the ligand conformation is energetically less favorable than that of 15a. This explains the loss of affinity and the resulting loss in residence time. We hypothesize that the reason for the long residence time of the dihydroindene analogs comes from the rearranged hydrogen bond network compared with MK-0812. It has been shown that receptor/ligand hydrogen bonds are crucial for the modulation of residence time within chemical series (Schmidtke et al., 2011; Tautermann et al., 2013) .
Using the Structural Information to Model Structurally Distinct CCR2 Antagonists As a result of intensive efforts in the development of CCR2 receptor antagonists (Horuk, 2009; Pease and Horuk, 2012) , a variety of structurally diverse antagonistic ligands have been identified. We used the combined structural information to generate plausible models for interesting antagonist representatives. In particular, the larger antagonists from the pyrimidine amide (PA) (patent WO2012/171863) class seem to penetrate deeper into the lipid bilayer ( Figure 5 ). Such extended binding modes, where the ligands partly bind in the GPCR/membrane interface, have been observed for other receptors, such as FFAR1 (Srivastava et al., 2014) . These extra-helical binding regions provide additional ligand optimization opportunities (e.g., pharmacokinetics and selectivity), as has been shown in the case of the selectivity of FFAR1 ligands over PPARs (Hamdouchi et al., 2016) . Compounds from the PA class are directly influenced by the G175N 4.60 mutation introduced for thermal stability. In DSF experiments, compound Ex15 showed a moderate stabilization by only 1.3 C in CCR2A-fl with the G175 4.60 N mutation, in contrast to other antagonists from other structural classes ( Figure 2B and Table S1 ). This supports our modeled binding mode of Ex15 ( Figure 5A ), in which the sulfonamide moiety directly interacts with H121 3.33 and T179 4.64 in WT CCR2. Close proximity to the N175 4.60 side chain may therefore introduce steric clashes. Ex15 superimposes with MK-0812, but further extends in the region beyond the tetrahydropyrane ring, leading to a significant selectivity over CCR5 from which the G175 4.60 N mutation was derived (Ki on hCCR2B = 3 nM, Ki on hCCR5 = 400 nM). The selectivity of Ex15 over CCR5 can be explained further by investigating the difference between the two chemokine receptors at position 3.33. In CCR2, H121 3.33 forms a direct hydrogen bond to Ex15, whereas in CCR5 this residue is replaced by F109 3.33 , which does not interact favorably with the sulfonamide moiety of Ex15. H121 3.33 has already been shown to be involved in CCR2/5 selectivity for other ligands, since the dual antagonist TAK-779 is not influenced by mutation of H121 3.33 . In contrast, the CCR2 selective Teijin ligand shows stronger effects upon this mutation, leading to the conclusion that CCR2 antagonistic activity may be gained through interaction with H121 3.33 (Hall et al., 2009) . Therefore, ligands from the PA structural class would provide a basis for the development of selective and potent CCR2 inhibitors, in contrast to MK-0812 and BMS-681, which are dual CCR2/CCR5 antagonists.
DISCUSSION
We have co-crystallized engineered constructs of CCR2 isoform A with the orthosteric antagonist MK-0812 and obtained two distinct crystal forms. Structure CCR2A-fl at 3.3 Å resolution was determined using crystals harvested conventionally from their mother liquor in standard glass sandwich plates (Caffrey and Cherezov, 2009 ). Structure CCR2A-DN.C (À) at 2.7 Å resolution was determined using the in meso in situ method (Huang et al., 2015) , which combines LCP crystallization, direct freezing of the crystallization droplet, and data collection in situ using serial crystallography. Serial crystallography is a rapidly advancing technique that has already been used to solve difficult membrane protein structures using both synchrotron and X-ray free electron laser (X-FEL) radiation sources (Cheng et al., 2017; Mizohata et al., 2018; Stauch and Cherezov, 2018; Suno et al., 2018) . Here, serial synchrotron crystallography facilitated structure determination of a GPCR by avoiding any crystal harvesting.
In the field of available chemokine receptor structures, CCR2 is the only example with independently derived crystal structures published by two different labs. Different strategies for construct design give evidence that a variety of options can be used for successful GPCR crystallization. In our study, we used the longer CCR2A receptor variant, which in comparison to CCR2B is mainly retained within the cell in monocytes (Tanaka et al., 2002) . Structure CCR2A-DN.C (À), reported in this study, has the C-terminal end of CCR2A resolved up to residue G321, in contrast to the last eight amino acids in CCR2B (CCR2A: 314-SLFHIALG-321 and CCR2B: 314-RYLSVFFR-321, Figure S1C ). Previously, a study including a chimeric CCR2-thrombin receptor revealed the existence of a potential retention signal between residues 316 and 349 (Wong et al., 1997) , in the highly flexible C-terminal domain. However, as shown with our structures, amino acids 315 to 321 do not exhibit any structural difference between the two receptor splicing variants and deliver no explanation for the mainly intracellular localization of CCR2A.
A significant difference between the CCR2B structure 5T1A and the structures presented in this paper is the grafting of the fusion protein into ICL3 ( Figure S1B ). Zheng and coworkers removed the native CCR2 residues between L226 5.62 and R240 6.32 (L226 5.62 -KTLLRCRNEKKRH-R240 6.32 ) and replaced this region with the T4L fusion in ICL3 flanked by the corresponding residues from the crystallized structure of the M2 muscarinic acetylcholine receptor (PDB: 3UON), resulting in amino acid sequence S226 5.62 -RASKSRI-T4L-PPPSREEK-K240 6.32 (Zheng et al., 2016) . In our construct design, we merely deleted residues 232 to 234 and fused rubredoxin between residues 231 and 235 of the WT CCR2 sequence. Therefore, in our structure we retain the native TM5 and TM6 sequences in a more native-like ICL3 environment. Although the presence of the rubredoxin fusion in ICL3 directly disturbs the G-protein binding site and prevents receptor activation as expected (data not shown), the comparable binding affinities for CCR2B-WT and the modified CCR2A receptor constructs for CCL2 and MK-0812 ( Figure S4 ) suggest that the fusion construct is a good model for studying ligand binding interactions.
Multiple orientations of helix 8 are observed in the three available CCR2 structures ( Figure 3C ). Although these differences could be due to crystal packing interactions, the different orientations observed suggest a relatively high flexibility of this helix. Helix 8 is reported to play potential roles in GPCR G-protein coupling and activation (Sensoy and Weinstein, 2015) , as well as in expression, internalization, phosphorylation, and dimerization (Sato et al., 2016) . Nuclear magnetic resonance studies with the b 2 -adrenergic receptor revealed that minor changes in the relative position of helix 8 do not directly contribute to the signaling process , but confirm the relative flexibility. Considering that these studies all are G-protein independent, the structural impact of the conformational changes in helix 8 during the signaling process cannot be fully evaluated.
GPCRs undergo significant further conformational changes during the signaling process. The only example of an agonistbound crystallized chemokine receptor, which reflects the fully activated conformational state, is US28 (Burg et al., 2015) . Conversely, CXCR4 (Wu et al., 2010) , CCR5 (Tan et al., 2013b; Zheng et al., 2017) , CCR9 (Oswald et al., 2016) , and CCR2B (Zheng et al., 2016) were crystallized in an antagonist-bound state. The inactive chemokine receptor structural signature, previously determined for the CCR5-maraviroc complex and the ternary CCR2B complex, is also adopted in our structures. The intracellular ends of TM3 and TM6 are located close to each other, and the conserved R138 3.50 (of the DRY motif) interacts with D137 3.49 and T77 2.39 , leading to a disruption of the G-protein binding site. The interaction of R138 3.50 with D 3.49 and T 2.39 is a common signature of antagonist-bound chemokine receptor structures (Tan et al., 2013b; Wu et al., 2010; Zheng et al., 2016) . In the US28-CX3CL1 complex, the arginine residue is twisted outward, making the G-protein binding pocket accessible (Burg et al., 2015) . In our structure, Y305 7.53 on TM7 (twisted outward) points toward TM2 ( Figure 3C ) and adopts an inactive conformation identical to CCR2B.
The orthosteric binding pocket and the mode of antagonist binding in the orthosteric site between CCR2B-BMS-681 and our structure are very similar. The main difference, and an intriguing finding of our study, consists in the polar interaction of the E291 7.39 side chain with the secondary amine of MK-0812. E 7.39 is present in most chemokine receptors and several mutation studies in literature have shown that this residue is important for small-molecule ligand binding to CXCR4, CCR5, CCR2, and US28 (Arimont et al., 2017) . In CXCR4 (Wu et al., 2010) and CCR5 structures (Tan et al., 2013b) the corresponding residues E288 7.39 and E283 7.39 are involved in hydrogen bond and ionic interactions with the co-crystallized ligands. Mutation studies of E 7.39 to A in CCR5 led to a loss of binding affinities for aplaviroc, SCH-C, and TAK-779 by more than a factor of ten (Maeda et al., 2006) . Previous mutation studies including different antagonists to CCR2, such as INCB3344 (Zweemer et al., 2014) , SB-282241, TAK-779, and Teijin (Berkhout et al., 2003) , demonstrated that E291 7.39 is a key residue in orthosteric chemokine receptor antagonist binding. The difference in the binding of E291 7.39 to MK-0812 and BMS-681 is an important finding for ligand-based modeling, where a superposition of the positively charged centers is a tempting interpretation, but would lead to an erroneous explanation of the binding mode.
In radioligand binding experiments, the binding of CCL2 is insignificantly or not at all affected by the mutations N14Q, C70 1.60 Y, G175 4.60 N, A241 6.33 D, and K311 8.49 E; by the rubredoxin fusion; or by the C-terminal truncation. Similarly, in CCR5 the analogous modifications had no effect on CCL3 binding, except for A233 6.33 D, which lowered the binding affinity by a factor of four (Tan et al., 2013b) . A233 6.33 D, which stabilizes the inactive form of the receptor, abolishes Ca 2+ signaling in CCR5 (Tan et al., 2013b) , as well as in CCR2 (data not shown). The N-terminal truncation of 28 amino acids disables binding of the endogenous ligand CCL2. This is not surprising, given the great importance of certain N-terminal residues in binding interactions, including, namely, residues 21-26 (Preobrazhensky et al., 2000) , the two conserved sulfated tyrosine residues Y26 and Y28 (Tan et al., 2013a) , and the disulfide bond connecting the N terminus with ECL3 (Kufareva, 2016) .
Residue K311 8.49 , located in the allosteric binding pocket, is highly conserved among chemokine receptors (68.4%) but not prevalent among class A GPCRs (Zweemer et al., 2014) . Residue K311 8.49 is reported to be directly involved in the binding of the allosteric antagonist CCR2-RA-[R] to CCR2 (Zheng et al., 2016) , and the affinity of CCR2-RA-[R] is decreased 10-fold by its mutation to alanine. While the orthosteric binding of the benzamide INCB3344 to CCR2 is not affected by the mutation of K311 8.49 to alanine (Zweemer et al., 2014) , in our construct the binding affinity of MK-0812 is decreased 2.6-fold by the mutation to glutamic acid. Reversion of K311 8.49 E to native K311 8.49 led to a decreased thermal stability of CCR2A-DN.C (À) compared with CCR2A-DN.C values by 6.0 C ( Figure S2D ). Interestingly, this decrease in stability of CCR2A-DN.C (À) was compensated for by a much higher increase in thermal stability invoked by the addition of MK-0812 (relative DTm 5.0 C).
Residue A241 6.33 is described to be involved in forming the inner hydrophobic part of the allosteric pocket in CCR2B (Zheng et al., 2016) . Based on modeling studies using the CCR5 structure, we have mutated A241 6.33 to aspartic acid, which supposedly results in an artificial salt bridge to R138 3.50 and stabilization of the inactive conformation by the so-called ''ionic lock'' Tan et al., 2013b) . In our structures the D241 6.33 side chain is not defined in the electron density, impeding the observation of a potential ionic lock, of which there is no evidence.
Although crystallization was performed in the presence of two different allosteric ligands, namely AZD-6942 and CCX140, we do not observe any difference in electron density in the known allosteric site nor elsewhere on the protein surface. Therefore, we concluded that we had crystallized the binary complex only. While we cannot provide a clear explanation for this behavior, we speculate that insufficient ligand exposure due to an unfavorable solubility/affinity ratio may have resulted in a lack of electron density.
Our binding models for compounds from the PA class postulate the formation of a polar interaction with H121 3.33 ; therefore compounds from the PA class are directly influenced by the proximity of the G175 4.60 N mutation, introduced for thermal stability. Indeed, a weaker binding affinity is observed based on DSF data, which supports the proposed modeled binding mode for Ex15 ( Figure 5) , where the proximity of the sulfonamide moiety may cause a steric clash with N175 4.60 . Modeling of the 5-Br-2,3-dihydro-1H-indene analog of MK-0812 suggests a rearrangement of the hydrogen bond network that led to changes in the residence time. There are several examples in the literature demonstrating the effect of water networks on drug-target residence times (Pan et al., 2013; Schmidtke et al., 2011; Schnapp et al., 2016; Tautermann et al., 2013) . Prolonging the residence time of CCR2 antagonists offers a compound efficacy enhancement strategy that may be able to overcome the lack of efficacy of previous clinical candidate molecules targeting CCR2. The CCR2A structures in complex with MK-0812 complement available structural information regarding the binding mode of CCL2 competitive small-molecular antagonists. The strong ionic interaction of MK-0812 with E291 7.39 was previously described as important for high-affinity binding of several CCR2 antagonists. The structures presented in this paper will facilitate future drug discovery efforts directed toward selective CCR2 antagonists.
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STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by Gisela Schnapp (gisela. schnapp@boehringer-ingelheim.com) .
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture High FiveÔ Cells (Hi5; cell line that originated from the ovarian cells of the cabbage looper, Trichoplusia ni) were cultured in Insect Xpress media (Lonza). Suspension cells were maintained in 1 L Fernbachflasks with an inoculation concentration of 0.2 to 0.3 x 10 6 cells/mL at 27 C and 60 rpm. Cells were splitted twice a week (three to four days), with a maximal passage number of 37. Large scale expression was performed in maximal 8.5 L using Wave cultivation bags (BIOSTATÒ, CultiBag RM, 20 L basic, Satorius Stedim) with a cell concentration at infection of 10 6 cells/mL. HEK293-6E cells (NRC-BRI; cell line from human embryo kidney, sex not specified) were cultured in FreeStyle F17 medium (Invitrogen) with 25 mg/ml geneticin, 0.1 % Pluronic F-68 and 1x GlutaMax (Invitrogen). Suspension cells were inoculated at 0.2-0.3 x 10 6 cells/mL and cultivated at 37 C with 5% CO 2 at 120 rpm. Subcultivation was performed over maximal 15 passages.
THP-1 cells (DSMZ ACC16, species human, male) were cultured in RPMI 1640 supplemented with 10 % FCS and 1 % NEA. CHO-K1_CCR2B cells (cell line originated from the ovary of chinese hamster and stably transfected with CCR2B) were cultured in Ham 0 s F12 medium (Biozym) supplemented with 10 % FCS, 1 % sodium pyruvate (Thermo) and 400 mg/ml G418 (Sigma).
METHOD DETAILS
Reagents n-Dodecyl ß-D-maltoside (DDM) was purchased from Anatrace and cholesterol hemisuccinate (CHS) from Sigma. To prepare DDM/ CHS stock solutions for purification 10 % DDM and 1.5 % CHS were dissolved in 100 mM HEPES pH 7.5 by sonication (3 cycles/ 30 min each). Stock solutions were stored at -20 C. To prepare Monoolein/Cholesterol stocks for crystallization monoolein (NuCheck Prep) was liquefied by heating up to 40 C and mixed with cholesterol (Sigma) in a glass vial at a ratio of 9:1 or 10:1 (w/w). The mixture was reheated at 40 C for 15 Min and subsequently vortexed for 3 min (7-10 cycles). Stock solutions were overlaid with N 2 and stored at -80 C.
All CCR2 antagonists were synthesized at Boehringer-Ingelheim Pharma GmbH & Co. KG according to given references in Table S1 (Xue et al., 2010 (Xue et al., , 2011 Cumming et al., 2012) .
Design and Expression of CCR2A Crystallization Constructs
Human CCR2 isoform A (Uniprot ID P41597-1) was modified for crystallization by truncation of N-terminal residues 1-28, C-terminal residues 322-374 and insertion of rubredoxin fusion (Rub) in ICL3. Using the CCR5 receptor as a homology model (Tan et al., 2013b) , residues C232-N234 in ICL3 were deleted and three point mutations (C70 1.60 Y, G175 4.60 N, A241 6.33 D) were introduced to enhance the thermostability of the detergent-solubilized receptor (CCR2A-DN.C (-)). Full-length constructs were additionally modified by replacing the glycosylation site N14Q and the point mutation K311 8.49 E (CCR2A-fl). Detailed construct information is included in Figure S1 .
To facilitate expression and purification, the coding sequence was optimized for insect cell expression and attached with a HA signal sequence at the N terminus, a PreScission protease site followed by a FLAG tag and a 10x His tag at the C terminus. Constructs were cloned into pFastBac1 vector (GeneArt). High-titer recombinant baculovirus (>10 9 viral particles per mL) was amplified using the Bac-to-Bac Baculovirus Expression System (Invitrogen) and used for infection of Trichoplusia ni (High Five) cells. High Five cells were infected at a density of 1x10 6 cells per ml with P3 virus and cultured at 27 C for 72 h. Cells were harvested by centrifugation at 2000 x g and stored at -80 C until use. by a stochastic conformation search (RMSD limit 1.0 Å , Energy cutoff 10 kcal/mol) as implemented in MOE. The lowest energy conformations were manually overlaid with the X-ray pose of MK-0812, with special emphasis on the shape superposition. Modeled binding modes were optimized by stepwise loosening the tethers on the heavy atoms (0.0, 0.5, 1.0) and finally an energy optimization is done by only tethering the protein backbone (tether 0.5).
QUANTIFICATION AND STATISTICAL ANALYSIS
DSF experiments were done in duplicates from one purified protein sample. SPA experiments were done in triplicates from one to two membranes (n=1-2).
DATA AND SOFTWARE AVAILABILITY
Data Resources PDB accession codes for the structures reported in this paper are 6GPS (structure CCR2A-fl) and 6GPX (structure CCR2A-DN.C (-)). 
Construct name
